{"entity":{"id":"nct06335355","kind":"trial","name":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","aka":[],"tldr":"A phase 2/3 trial of adebrelimab, SHR-8068, pemetrexed, carboplatin and other drugs in lung cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, not yet recruiting.","summary":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients is a phase 2/3, randomised interventional study registered as NCT06335355 by Shanghai Shengdi Pharmaceutical Co., Ltd, with a registry enrolment figure of 401 participants, started 2024-03 and due to reach its primary completion in 2028-10. Interventions recorded: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin; Camrelizumab + Pemetrexed + Carboplatin; Adebrelimab + Pemetrexed + Carboplatin. Conditions listed: Non-squamous Non-small Cell Lung Cancer. Primary outcome: Investigator-assessed Objective Response Rate (Phase One); Overall Survival (Phase Two). Lung eligibility wording from the registry: \"Diagnosed with advanced or metastatic non-squamous NSCLC (non-small cell lung cancer) confirmed by histology or cytology\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06335355","url":"https://clinicaltrials.gov/study/NCT06335355"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["adebrelimab","shr-8068","pemetrexed","carboplatin","camrelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06335355","phase":"2/3","setting":"A Phase II/III, Randomized, Open-label, Parallel-controlled, Multicenter Study of Adebrelimab (SHR-1316) in Combination With SHR-8068 and Platinum-based Doublet Chemotherapy as First-line Treatment in Advanced or Metastatic NSCLC Patients With STK11/KEAP1/KRAS Mutations","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","enrolled":401,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06335355/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}